欧洲侵入性皮肤鳞状细胞癌诊疗指南2026更新:诊断与预防
欧洲多学科专家组基于最新文献与共识更新2023版指南,针对免疫功能正常及抑制患者的侵入性皮肤鳞状细胞癌(CSCC)提出诊断与预防推荐,并新提出难治性CSCC五分类,涵盖常见型、局部晚期及转移性类型。诊断分三步:临床皮肤镜初筛后组织病理确诊,再行分期检查并纳入AJCC8或BWH分期系统;预防推荐口服烟酰胺与防晒措施。
要点
- CSCC诊断三步法:临床皮肤镜初筛→组织病理确诊→分期检查并纳入AJCC8或BWH分期系统
- 新提出难治性CSCC五分类:组1-2为复杂常见型,组3局部晚期,组4-5区域或远处转移
- 风险因素越多复发转移风险越高,据此区分低危与高危CSCC
核心结论
- CSCC可分类为易治(绝大多数)或难治,并按复发转移风险分为低危与高危。
- 新提出EADO 2025年发布的难治性CSCC五组分类,反映常见临床挑战。
研究设计与样本
- 由EADO、EDF、ESTRO、UEMS皮肤性病学分部及EORTC多学科专家协作制定,基于当前文献与专家共识更新2023版。
- 第一部分针对免疫功能正常及免疫抑制患者的诊断与预防。
主要发现
- CSCC在白种人群中占所有皮肤恶性肿瘤的20%。
- 难治性CSCC包括组1-2(肿瘤和/或患者特征或多发导致治疗复杂的常见型亚组)、组3(局部晚期)、组4(区域转移)和组5(远处转移)。
- 诊断第一步基于临床与皮肤镜特征,始终经组织病理学确认。
- 风险因素存在定义高危CSCC,风险因素越多风险越高。
- 第二步分期包括体格检查及有指征时的影像学检查;第三步将临床、组织学与影像学发现纳入分期系统。
关键数值与推荐
- 常用分期系统为AJCC第8版(AJCC8)与Brigham and Women's Hospital(BWH)系统。
- 预防策略包括口服烟酰胺与防晒措施。
临床怎么用
- 临床疑似CSCC应先行皮肤镜检查,再经组织病理确诊。
- 确诊后根据指征行体格检查与影像学分期,并采用AJCC8或BWH系统进行分期。
- 评估风险因素数量以区分低危与高危,指导治疗强度。
- 对免疫抑制患者同样适用本诊断与预防推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS)-Dermatology Venereology, and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update guideline recommendations on CSCC (previous version 2023), based on current literature and expert consensus. Part 1 of the guidelines addresses diagnostics and prevention in immunocompetent as well as immunosuppressed patients. CSCC may be classified as easy-to-treat (vast majority) or difficult-to-treat, common primary CSCC, and is further defined as low risk or higher risk depending on the risk of recurrence or metastasis. A new classification of five groups of difficult-to-treat CSCC (DTT-CSCC) is proposed, published in 2025 by EADO experts and reflecting the commonly encountered clinical challenges. Difficult-to-treat (DTT) CSCC includes DTT-common CSCC groups 1 and 2 (which correspond to a subgroup of common CSCC that are complex to treat due to tumor and/or patient characteristics or multiplicity), DTT-CSCC group 3 corresponding to locally advanced CSCC, and DTT-CSCC groups 4 and 5 corresponding to CSCC with locoregional or distant metastases, respectively. The first step of diagnostics is based on clinical and dermatoscopic features, and is always confirmed by histopathology. The presence of risk factors characterizes higher risk CSCC, and the more risk factors, the higher the risk. After the histological diagnosis of CSCC has been established, the second step includes staging procedures, such as physical examination and, when indicated, imaging. In the third and final step, the clinical, histologic and radiologic findings are incorporated into staging systems. The more widely used staging systems are the American Joint Committee on Cancer 8th edition (AJCC8) and the Brigham and Women's Hospital (BWH) systems. Prevention strategies include oral nicotinamide and sun protection measures.
引用
- Stratigos AJ, Dessinioti C, Garbe C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026. Eur J Cancer. 2026. PMID: 42248744. doi:10.1016/j.ejca.2026.116763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。